B. Riley Forecasts Vaxart's FY2029 Earnings (NASDAQ:VXRT)

Vaxart, Inc. (NASDAQ:VXRT - Free Report) - Equities researchers at B. Riley issued their FY2029 EPS estimates for shares of Vaxart in a note issued to investors on Thursday, May 29th. B. Riley analyst M. Mamtani forecasts that the biotechnology company will post earnings of $0.13 per share for the year. B. Riley currently has a "Buy" rating and a $2.00 price target on the stock. The consensus estimate for Vaxart's current full-year earnings is ($0.39) per share.

Vaxart (NASDAQ:VXRT - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.07). The firm had revenue of $20.88 million for the quarter, compared to analysts' expectations of $2.85 million. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%.

Separately, Wall Street Zen upgraded Vaxart to a "hold" rating in a research report on Thursday, May 22nd.

Vaxart Stock Down 6.5%

Shares of NASDAQ VXRT traded down $0.03 during midday trading on Friday, reaching $0.44. 1,302,992 shares of the company were exchanged, compared to its average volume of 2,441,430. The stock has a market cap of $99.69 million, a P/E ratio of -1.07 and a beta of 1.27. Vaxart has a one year low of $0.29 and a one year high of $1.07. The stock's 50-day moving average price is $0.40 and its 200-day moving average price is $0.56.

Institutional Trading of Vaxart

Several institutional investors have recently modified their holdings of the business. Geode Capital Management LLC grew its position in shares of Vaxart by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 2,601,139 shares of the biotechnology company's stock valued at $1,723,000 after buying an additional 57,911 shares during the last quarter. Silverarc Capital Management LLC boosted its stake in shares of Vaxart by 7.8% in the 4th quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company's stock valued at $714,000 after purchasing an additional 77,782 shares during the last quarter. Squarepoint Ops LLC boosted its position in Vaxart by 95.0% during the fourth quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company's stock valued at $342,000 after acquiring an additional 251,789 shares during the last quarter. Jones Financial Companies Lllp boosted its position in shares of Vaxart by 276,364.7% during the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock valued at $196,000 after purchasing an additional 478,111 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Vaxart during the 4th quarter worth approximately $129,000. Institutional investors own 18.05% of the company's stock.

Insider Transactions at Vaxart

In other Vaxart news, insider Steven Lo acquired 100,000 shares of Vaxart stock in a transaction that occurred on Monday, May 19th. The shares were bought at an average price of $0.49 per share, with a total value of $49,000.00. Following the completion of the purchase, the insider now directly owns 100,000 shares in the company, valued at $49,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 2.90% of the company's stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.